{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:30:06Z","timestamp":1787070606950,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background:<\/jats:title>\n Multiple myeloma (MM) is characterised by an increased number of monoclonal immunoglobulin-producing plasma cells that malignantly grow in the bone marrow. Lung cancer is one of the most common malignancies and at the advanced stage may become metastatic to the bone. Rarely, MM and lung cancer are synchronously present in the same patient.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods,<\/jats:title>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In this report, we describe five cases of MM synchronous with lung adenocarcinoma including \u03bb light chain in three cases and \u03f0 light chain in two cases. Two patients achieved complete remission, and no progression was seen in two patients.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In conclusion, synchronous MM and lung adenocarcinoma are clinically rare, and diagnosis should be made scrupulously based on morphology, immunology, cytogenetics, molecular biology and biopsy pathology.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_530_22","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T04:16:59Z","timestamp":1717129019000},"page":"390-395","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Synchronous multiple myeloma and lung adenocarcinoma: A clinical series"],"prefix":"10.4103","volume":"67","author":[{"given":"Fang","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Hematology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics,","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-642-21892-7_4","article-title":"Bisphosphonates:Prevention of bone metastases in lung cancer","volume":"192","author":"Decoster","year":"2012","journal-title":"Recent Results Cancer Res"},{"key":"R4-20240829","first-page":"239","article-title":"Patients with multiple myeloma and solid tumors:Six case reports","volume":"17","author":"Christou","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.1067","article-title":"Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma","volume":"67","author":"Oshima","year":"2001","journal-title":"Am J Hematol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer:The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4143\/crt.2004.36.5.338","article-title":"Three cases of synchronous solid tumor and multiple myeloma","volume":"36","author":"Ji","year":"2004","journal-title":"Cancer Res Treat"},{"key":"R9-20240829","first-page":"725","article-title":"[Association of multiple myeloma and solid neoplasms:analysis of 13 cases","volume":"199","author":"Todol\u00edParra","year":"1999","journal-title":"Rev Clin Esp"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"e5787","DOI":"10.1097\/MD.0000000000005787","article-title":"Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma:A case report","volume":"96","author":"Zuo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1200\/JCO.2008.19.6287","article-title":"Synchronous presentation of multiple myeloma and lung cancer","volume":"26","author":"Agarwal","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de","year":"2011","journal-title":"J Immunol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab:A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4143\/crt.2012.44.1.63","article-title":"Five cases report of solid tumor synchronously with hematologic malignancy","volume":"44","author":"Cui","year":"2012","journal-title":"Cancer Res Treat"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_530_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:32:09Z","timestamp":1787067129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_530_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_530_22","relation":{},"ISSN":["0377-4929","0974-5130"],"issn-type":[{"value":"0377-4929","type":"print"},{"value":"0974-5130","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"2023-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}